促红细胞生成素对极低胎龄新生儿肾脏相关结局的影响:多中心双盲安慰剂对照随机临床试验
该研究为多中心双盲安慰剂对照随机试验的辅助研究,评估极低胎龄新生儿随机接受促红细胞生成素或安慰剂后住院期间及校正胎龄22-26个月时的肾脏相关结局。结果显示促红细胞生成素组与安慰剂组在严重急性肾损伤等住院结局无显著差异,但促红细胞生成素组收缩压>90百分位的发生率更低(aOR 0.6;95%CI 0.39-0.92)。
要点
- 极低胎龄新生儿住院期间严重急性肾损伤发生率为18.2%。
- 促红细胞生成素未显著降低住院期间严重急性肾损伤或任何急性肾损伤风险。
- 促红细胞生成素可能降低校正胎龄22-26个月时收缩压>90百分位的风险。
核心结论
- 极低胎龄新生儿住院期间急性肾损伤及校正胎龄22-26个月时肾脏相关问题发生率高。
- 重组促红细胞生成素可能保护极低胎龄新生儿免受长期收缩压升高,但似乎不能预防急性肾损伤、低估算肾小球滤过率、白蛋白尿或舒张压升高。
研究设计与样本
- 多中心双盲安慰剂对照随机临床试验的辅助研究。
- 研究对象为极低胎龄新生儿,随机接受促红细胞生成素或安慰剂。
- 评估住院期间及校正胎龄22-26个月时的肾脏相关结局。
主要发现
- 严重(2期或3期)急性肾损伤的患病率为18.2%。
- 促红细胞生成素组与安慰剂组在住院期间严重急性肾损伤、任何急性肾损伤及第0、7、9、14天血清肌酐/胱抑素C值方面无统计学显著差异。
- 校正胎龄22-26个月时,16%的队列估算肾小球滤过率<90 mL/min/1.73 m2,35.8%尿白蛋白/肌酐比值>30 mg/g,23%收缩压>同龄第95百分位,40%舒张压>同龄第95百分位。
- 促红细胞生成素组收缩压>90百分位的发生率更低(P < .04),控制胎龄、站点和同胞关系后该关联仍存在(aOR 0.6;95% CI 0.39-0.92)。
- 两组在校正胎龄2年随访时估算肾小球滤过率、白蛋白/肌酐比值、收缩压>95百分位率或舒张压>90或>95百分位率方面无统计学显著差异。
临床怎么用
- 极低胎龄新生儿需关注住院期间急性肾损伤及远期肾脏相关指标异常。
- 促红细胞生成素可能有助于降低远期收缩压升高风险,但不应期望其预防急性肾损伤或白蛋白尿。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether extremely low gestational age neonates (ELGANs) randomized to erythropoietin have better or worse kidney-related outcomes during hospitalization and at 22-26 months of corrected gestational age (cGA) compared with those randomized to placebo. STUDY DESIGN: We performed an ancillary study to a multicenter double-blind, placebo-controlled randomized clinical trial of erythropoietin in ELGANs. RESULTS: The prevalence of severe (stage 2 or 3) acute kidney injury (AKI) was 18.2%. We did not find a statistically significant difference between those randomized to erythropoietin vs placebo for in-hospital primary (severe AKI) or secondary outcomes (any AKI and serum creatinine/cystatin C values at days 0, 7, 9, and 14). At 22-26 months of cGA, 16% of the cohort had an estimated glomerular filtration rate (eGFR) <90 mL/min/1.73 m2, 35.8% had urine albumin/creatinine ratio >30 mg/g, 23% had a systolic blood pressure (SBP) >95th percentile for age, and 40% had a diastolic blood pressure (DBP) >95th percentile for age. SBP >90th percentile occurred less often among recipients of erythropoietin (P < .04). This association remained even after controlling for gestational age, site, and sibship (aOR 0.6; 95% CI 0.39-0.92). We did not find statistically significant differences between treatment groups in eGFR, albumin/creatinine ratio, rates of SBP >95th percentile, or DBP >90th or >95th percentiles at the 2 year follow-up visit. CONCLUSIONS: ELGANs have high rates of in-hospital AKI and kidney-related problems at 22-26 months of cGA. Recombinant erythropoietin may protect ELGANs against long-term elevated SBP but does not appear to protect from AKI, low eGFR, albuminuria, or elevated DBP at 22-26 months of cGA.
引用
- Askenazi DJ, Heagerty PJ, Schmicker RH, et al. The Impact of Erythropoietin on Short- and Long-Term Kidney-Related Outcomes in Neonates of Extremely Low Gestational Age. Results of a Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial. J Pediatr. 2021. PMID: 33484699. doi:10.1016/j.jpeds.2021.01.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。